A Phase 3 interventional study of voclosporin and Placebo in Psoriasis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 31 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 303 studies in Psoriasis with a site in Canada — 15 open to participants now, 32 under way, 14 of them phase 3. Psoriasis · Canada.
Among the 303 studies in Psoriasis with a site in Canada, this one is the 83rd largest by enrollment of the 272 interventional ones that give a count, is one of 4 that started in 2004, is one of 139 in phase 3, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →15 of the 303 studies in Psoriasis with a site in Canada are open now. Recruiting first, the newest first:
Oruka Therapeutics, Inc. · Sites in Canada, United States
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Argentina and 13 more countries
Ages 12–17
Chronicle Academy · Sites in Canada
Ages 18+
UCB Biopharma SRL · Sites in Canada, United States, China and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Argentina and 22 more countries
Ages 40+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
303 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 92 · Phase 3 140 · Phase 4 26
First in 2001; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 227 across the 272 interventional studies, 419 across the 31 observational. Of the 268 that completed or were terminated, 184 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
270 of 303 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 3 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
6 of the studies in Psoriasis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382051Novartis PharmaceuticalsModifying PEST for Psoriatic Arthritis Screening | 2026-12-31 |
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07370766Chronicle AcademyImpact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada | 2027-05-30 |
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
| NCT07914231Coultreon BiopharmaA Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 303 studies in Psoriasis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.
Psoriasis is a chronic skin condition that can have a significant impact on patient's physical and mental well being. The most common form of psoriasis is plaque psoriasis. Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as cyclosporine A, but also has an improved toxicity profile.
Comparison(s): Voclosporin at 3 dose levels (0.2, 0.3, and 0.4 mg/kg twice a day)compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Voclosporin 0.2 mg/kg po BID
Drug: voclosporin
Voclosporin 0.3 mg/kg po BID
Drug: voclosporin
Voclosporin 0.4 mg/kg po BID
Drug: voclosporin
voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
Placebo
Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.
Proportion of subjects achieving a PASI-75 at 12 weeks at each of the 3 dose levels of voclosporin.
Time frame: Twelve Weeks
To Investigate the Safety and Tolerability of Voclosporin.
Time frame: Twelve and twenty four weeks
To Investigate the Pharmacokinetics and Pharmacodynamics of Voclosporin After Chronic Dosing in a Subset of Subjects.
Time frame: Twelve and twenty four weeks
To Evaluate the Effect of Voclosporin on Subject Quality of Life
Time frame: Twelve and twenty four weeks
| Milestone | Placebo 1 | ISA247 2 | ISA247 3 | ISA247 4 |
|---|---|---|---|---|
| Started | 115 | 107 | 113 | 116 |
| Completed | 92 | 76 | 91 | 83 |
| Not completed | 23 | 31 | 22 | 33 |
Proportion of subjects achieving a PASI-75 at 12 weeks at each of the 3 dose levels of voclosporin.
| Participants | Placebo | Voclosporin 0.2 | Voclosporin 0.3 | Voclosporin 0.4 |
|---|---|---|---|---|
| Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin. | 4 | 14 | 26 | 44 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/115 (0.9%) | 4/115 (3.5%) | 62/115 (53.9%) |
| Voclosporin 0.2 | 0/107 (0%) | 2/107 (1.9%) | 67/107 (62.6%) |
| Voclosporin 0.3 | 1/113 (0.9%) | 4/113 (3.5%) | 65/113 (57.5%) |
| Voclosporin 0.4 | 0/116 (0%) | 1/116 (0.9%) | 80/116 (69%) |
| Event | Placebo | Voclosporin 0.2 | Voclosporin 0.3 | Voclosporin 0.4 |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 0/115 | 1/107 | 0/113 | 0/116 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/115 | 1/107 | 0/113 | 0/116 |
| Myocardial InfarctionCardiac disorders | 0/115 | 0/107 | 1/113 | 0/116 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/115 | 0/107 | 1/113 | 0/116 |
| Parapharyngeal AbscessInfections and infestations | 0/115 | 0/107 | 1/113 | 0/116 |
| Accidental DeathGeneral disorders | 0/115 | 0/107 | 1/113 | 0/116 |
| Bile duct cancerHepatobiliary disorders | 1/115 | 0/107 | 0/113 | 0/116 |
| AnxietyPsychiatric disorders | 1/115 | 0/107 | 0/113 | 0/116 |
| Femur fractureMusculoskeletal and connective tissue disorders | 1/115 | 0/107 | 0/113 | 0/116 |
| Radius fractureMusculoskeletal and connective tissue disorders | 1/115 | 0/107 | 0/113 | 0/116 |
| Event | Placebo | Voclosporin 0.2 | Voclosporin 0.3 | Voclosporin 0.4 |
|---|---|---|---|---|
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 27/115 | 27/107 | 34/113 | 26/116 |
| HeadacheNervous system disorders | 12/115 | 18/107 | 12/113 | 26/116 |
| Upper respiratory tract infectionInfections and infestations | 9/115 | 12/107 | 13/113 | 12/116 |
| DiarrhoeaGastrointestinal disorders | 3/115 | 2/107 | 4/113 | 12/116 |
| HypertensionVascular disorders | 7/115 | 8/107 | 8/113 | 12/116 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/115 | 2/107 | 3/113 | 11/116 |
| VomitingGastrointestinal disorders | 4/115 | 3/107 | 2/113 | 7/116 |
| Blood pressure increasedVascular disorders | 5/115 | 4/107 | 5/113 | 7/116 |
| Glomerular Filtration Rate DecreasedInvestigations | 0/115 | 0/107 | 1/113 | 7/116 |
| Back painMusculoskeletal and connective tissue disorders | 2/115 | 5/107 | 6/113 | 7/116 |
| Age, Categorical(Participants) | Placebo | Voclosporin: 0.2 | Voclosporin: 0.3 | Voclosporin: 0.4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 115 | 107 | 113 | 116 | 451 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Voclosporin: 0.2 | Voclosporin: 0.3 | Voclosporin: 0.4 | Total |
|---|---|---|---|---|---|
| Median | 41 (19 to 63) | 42 (18 to 62) | 40 (18 to 65) | 41 (18 to 65) | 41 (18 to 65) |
| Sex: Female, Male(Participants) | Placebo | Voclosporin: 0.2 | Voclosporin: 0.3 | Voclosporin: 0.4 | Total |
|---|---|---|---|---|---|
| Female | 45 | 44 | 25 | 35 | 149 |
| Male | 70 | 63 | 88 | 81 | 302 |
| Region of Enrollment(participants) | Placebo | Voclosporin: 0.2 | Voclosporin: 0.3 | Voclosporin: 0.4 | Total |
|---|---|---|---|---|---|
| Canada | 115 | 107 | 113 | 116 | 451 |
Plan to share: No
The record gives a start of Dec 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2023, 17 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Aurinia Pharmaceuticals Inc.